Redefining Prostate Cancer Diagnostics in China: The Emerging Role of MRI alongside PSA Testing
Oncology Advances · 2023
DOI: 10.14218/ona.2023.00036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Advances, 2023. Verfasst von Xiaolei Zhao und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Prostate cancer remains a significant global health issue, consistently ranking as the second most common cancer among men worldwide and a leading cause of cancer-related deaths.1,2 In the United States, prostate cancer is the most frequently diagnosed malignancy in men and the second leading cause of cancer-related death. 2 The conventional diagnostic regime, heavily reliant on Prostate-Specific Antigen (PSA) levels, is increasingly recognized for its limitations due to high sensitivity that results in a substantial rate of false positives.3,4 As an alternative, Magnetic Resonance Imaging (MRI) has emerged as a promising complementary diagnostic tool.5,6 Pivotal studies by Robinson et al. and the ReIMAG-INE research group have highlighted MRI's potential to diminish biopsy rates and enhance the accuracy of tumor-grade detection.7,8Nevertheless, these advancements underscore the necessity for careful patient selection to avoid an uptick in false negatives.This commentary aims to dissect the impact of MRI within the context of prostate cancer diagnostics, proposing an integrated approach that combines MRI with traditional PSA testing, and exploring the
Zitieren
APA
Zhao, X., Zhou, F., & Ma, W. (2023). Redefining Prostate Cancer Diagnostics in China: The Emerging Role of MRI alongside PSA Testing. Oncology Advances. https://doi.org/10.14218/ona.2023.00036
Vancouver
Zhao X, Zhou F, Ma W. Redefining Prostate Cancer Diagnostics in China: The Emerging Role of MRI alongside PSA Testing. Oncology Advances. 2023. doi:10.14218/ona.2023.00036
BibTeX
@article{Zhao2023,
author = {Zhao, Xiaolei and Zhou, Fenghai and Ma, Wenxue},
title = {Redefining Prostate Cancer Diagnostics in China: The Emerging Role of MRI alongside PSA Testing},
journal = {Oncology Advances},
year = {2023},
doi = {10.14218/ona.2023.00036}
}
EUVIMED